モルヒネ薬市場-世界の産業規模、動向、機会、予測、セグメント、製品別、用途別、地域別、競合、2019年～2029年

モルヒネ薬の世界市場規模は2023年に242億7,000万米ドルとなり、予測期間では2029年までCAGR 4.71％で安定した成長が予測されています。

モルヒネ薬の世界市場は、効果的な疼痛管理ソリューションに対する広範な需要に牽引され、医薬品業界の重要な構成要素となっています。オピオイド鎮痛薬であるモルヒネは、その強力な鎮痛作用で知られ、中等度から重度の痛みに処方されることが多いです。同市場の成長は、慢性疼痛、手術後の回復、がん関連疼痛の発生率の上昇など、いくつかの要因に支えられています。慢性疼痛は世界的に蔓延している健康問題であり、市場の拡大に大きく寄与しています。関節炎、腰痛、神経障害性疼痛などの症状は、十分な緩和のためにモルヒネのような強力な鎮痛薬を必要とします。強い痛みを伴うことが多いがんの有病率の増加は、緩和ケアの要としてモルヒネ薬の需要を促進しています。手術後の回復は、モルヒネ薬市場のもう一つの重要な促進要因です。外科手術の後、患者はしばしば様々な程度の疼痛を経験し、急性疼痛管理に有効なモルヒネが術後の快適性を高めるために頻繁に処方されます。市場力学は、製剤やドラッグデリバリー方法の進歩によっても影響を受ける。製薬会社はモルヒネの製剤を最適化するための研究開発に投資しており、バイオアベイラビリティの向上、副作用の最小化、患者のコンプライアンス向上を目指しています。しかし、モルヒネ薬市場に課題がないわけではないです。オピオイドの誤用、中毒、副作用の可能性に対する懸念が、規制当局の監視を促しています。患者が効果的な鎮痛剤にアクセスできるようにすることと、オピオイド関連の懸念に対処することの間で微妙なバランスを取ることが、市場の持続的成長にとって極めて重要です。市場情勢は、ヘルスケア・インフラ、疼痛管理の慣行、規制状況の地域差によって形成されています。北米と欧州は、医療制度が確立されており、疼痛管理戦略に対する認識が高いため、有力な市場となっています。結論として、モルヒネ薬の世界市場は、様々な形態の疼痛を効果的に管理するための強力な鎮痛薬に対する切実なニーズによって牽引されています。世界中のヘルスケアシステムが疼痛管理の複雑さに取り組んでいる中、モルヒネ薬市場は、困難な疼痛状態に直面している患者に緩和を提供し、生活の質を向上させる上で重要な役割を担っています。

市場促進要因

慢性疼痛の発生率の上昇

認知度と利用しやすさ

主な市場課題

副作用と耐性

乱用抑止製剤

主要市場動向

個別化医療への注目の高まり

ドラッグデリバリーシステムの進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のモルヒネ薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（即効性/短時間作用型オピオイド、徐放性/長時間作用型オピオイド）
  • 用途別（鎮痛、麻酔、咳止め、下痢止め、依存症治療）
  • 企業別（2023）
  • 地域別
• 市場マップ

第6章 北米のモルヒネ薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のモルヒネ薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のモルヒネ薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のモルヒネ薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのモルヒネ薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併および買収（該当する場合）
• 製品の発売（該当する場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Hikma Pharmaceuticals plc
• Pfizer Inc.
• AbbVie Inc.
• Sanofi S.A
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Endo, Inc.
• Verve Health Care Ltd.
• Mallinckrodt Pharmaceuticals

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Morphine Drugs Market was valued at USD 24.27 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 4.71% through 2029. The Global Morphine Drugs Market is a critical component of the pharmaceutical industry, driven by the widespread demand for effective pain management solutions. Morphine, an opioid analgesic, is renowned for its potent pain-relieving properties and is often prescribed for moderate to severe pain. The market's growth is underpinned by several factors, including the rising incidence of chronic pain conditions, post-surgical recovery, and cancer-related pain. Chronic pain, a pervasive health issue globally, contributes significantly to the market's expansion. Conditions such as arthritis, back pain, and neuropathic pain necessitate potent analgesics like morphine for adequate relief. The increasing prevalence of cancer, often accompanied by intense pain, fuels the demand for morphine drugs as a cornerstone in palliative care. Post-surgical recovery is another key driver of the morphine drugs market. Following surgical procedures, patients often experience varying degrees of pain, and morphine, with its efficacy in managing acute pain, is frequently prescribed to enhance postoperative comfort. The market's dynamics are also influenced by ongoing advancements in drug formulations and delivery methods. Pharmaceutical companies are investing in research and development to optimize morphine formulations, aiming to improve bioavailability, minimize side effects, and enhance patient compliance. However, the morphine drugs market is not without challenges. Concerns about opioid misuse, addiction, and the potential for adverse effects have prompted regulatory scrutiny. Striking a delicate balance between ensuring patient access to effective pain relief and addressing opioid-related concerns is crucial for the sustainable growth of the market. Geographically, the market's landscape is shaped by regional variations in healthcare infrastructure, pain management practices, and regulatory frameworks. North America and Europe are prominent markets due to established healthcare systems and higher awareness of pain management strategies. In conclusion, the Global Morphine Drugs Market is driven by the imperative need for potent analgesics to manage various forms of pain effectively. As healthcare systems worldwide grapple with the complexities of pain management, the market for morphine drugs remains a critical player in providing relief and improving the quality of life for patients facing challenging pain conditions.

Key Market Drivers

Rising Incidence of Chronic Pain

The Global Morphine Drugs Market is significantly influenced by the rising incidence of chronic pain worldwide. Chronic pain, characterized by persistent discomfort lasting for an extended period, is a pervasive health concern affecting millions of individuals. Conditions such as arthritis, neuropathic pain, and musculoskeletal disorders contribute to the escalating prevalence of chronic pain. As populations age and chronic diseases become more widespread, the demand for effective pain management solutions, including potent analgesics like morphine, intensifies.

Chronic pain negatively impacts the quality of life, functional abilities, and mental well-being of affected individuals. The debilitating nature of chronic pain underscores the critical need for robust analgesic medications to provide relief and improve overall patient outcomes. Morphine, known for its efficacy in managing severe pain, emerges as a cornerstone in addressing the complexities of chronic pain conditions. The increasing burden of chronic pain is particularly notable in aging populations, where degenerative conditions and age-related ailments contribute to heightened pain experiences. Lifestyle factors, occupational stress, and sedentary habits further contribute to the prevalence of chronic pain across diverse demographic groups. Pharmaceutical companies and healthcare providers recognize the imperative to address the challenges posed by chronic pain, driving research and development efforts to enhance pain management strategies. Morphine drugs play a pivotal role in this landscape, offering a potent and established option for patients experiencing moderate to severe chronic pain. The rising incidence of chronic pain not only propels the demand for morphine drugs but also underscores the importance of comprehensive pain management approaches in global healthcare systems. Balancing effective pain relief with considerations for potential risks and side effects remains a key focus in optimizing the use of morphine and ensuring its continued relevance in addressing the complex landscape of chronic pain.

Awareness and Accessibility

Awareness and accessibility play pivotal roles in shaping the dynamics of the Global Morphine Drugs Market, influencing the adoption, prescription, and overall utilization of morphine for pain management. Increased awareness among healthcare professionals, patients, and the general public regarding the efficacy of morphine in addressing moderate to severe pain is crucial in driving its demand. Healthcare providers are key influencers in raising awareness about morphine as a potent analgesic. Continuous medical education programs and initiatives focused on pain management contribute to enhancing the understanding of morphine's role, benefits, and potential risks among healthcare professionals. This heightened awareness enables more informed prescribing practices and promotes responsible use. Patient awareness is equally essential in fostering acceptance and adherence to morphine therapy. Education campaigns that highlight the benefits, proper usage, and potential side effects of morphine contribute to destigmatizing opioid medications and addressing concerns about addiction. Empowering patients with accurate information ensures they actively participate in treatment decisions and follow prescribed regimens, optimizing the therapeutic outcomes of morphine. Accessibility to morphine is a critical determinant of its utilization, particularly in regions with varying healthcare infrastructure and regulatory frameworks. Ensuring that morphine is available and affordable in healthcare settings is vital for addressing pain effectively. Efforts to improve accessibility involve collaboration between healthcare providers, pharmaceutical manufacturers, and regulatory bodies to streamline distribution channels and eliminate barriers to availability. Global variations in opioid accessibility highlight the need for concerted efforts to address disparities. In some regions, regulatory frameworks may impede accessibility due to concerns about opioid misuse. Advocacy for balanced regulations that prioritize patient access while mitigating potential risks contributes to creating an environment conducive to the appropriate use of morphine. As awareness spreads and accessibility improves, the Global Morphine Drugs Market is poised to meet the increasing demand for effective pain management solutions. Striking a balance between responsible prescribing, patient education, and regulatory considerations ensures that morphine remains a valuable and accessible asset in the global healthcare landscape.

Key Market Challenges

Side Effects and Tolerance

Side effects and tolerance present significant challenges in the Global Morphine Drugs Market, influencing the effective management of pain while navigating potential drawbacks. Morphine, as an opioid analgesic, is known for its potent pain-relieving properties, but its use can be associated with a range of side effects. Common side effects of morphine include sedation, constipation, nausea, and respiratory depression. Balancing the need for adequate pain relief with these adverse effects requires careful consideration by healthcare professionals. Addressing and mitigating side effects become imperative to enhance patient comfort and adherence to prescribed regimens. Tolerance, a phenomenon where the body adapts to a drug, can occur with prolonged morphine use. As tolerance develops, patients may require higher doses to achieve the same level of pain relief. Managing tolerance poses a challenge as it involves careful monitoring, dose adjustments, and potentially exploring alternative pain management strategies. Respiratory depression, a serious side effect of opioids like morphine, underscores the need for vigilant monitoring, particularly in patients with respiratory conditions. Striking a balance between providing effective pain relief and minimizing the risk of respiratory depression is a constant challenge for healthcare professionals. Efforts to address these challenges include the development of extended-release formulations that aim to provide sustained pain relief with reduced frequency of dosing, potentially minimizing certain side effects. Research focuses on the optimization of drug delivery methods and formulations to improve the therapeutic profile of morphine. Patient education plays a crucial role in managing side effects and tolerance.

Abuse-Deterrent Formulations

Abuse-deterrent formulations represent a critical development in the Global Morphine Drugs Market, aiming to mitigate the risk of opioid misuse while ensuring access to effective pain management. Morphine, as an opioid analgesic, has faced concerns related to its potential for abuse, leading pharmaceutical companies to innovate and create formulations that deter misuse. Abuse-deterrent formulations incorporate technologies that make it more challenging for individuals to tamper with the drug for recreational purposes. These technologies aim to prevent crushing, chewing, or dissolving the medication, which are common methods used to extract the active ingredient for illicit use. The introduction of abuse-deterrent formulations aligns with broader efforts to address the opioid epidemic and enhance patient safety. These formulations not only safeguard against potential abuse but also contribute to minimizing the societal impact of opioid-related issues, including addiction and overdose. Common strategies employed in abuse-deterrent formulations include the use of physical barriers, aversive agents, or combinations thereof. Physical barriers make it difficult to alter the drug's form, while aversive agents, such as bitter substances, deter intentional misuse by rendering the drug unappealing. Despite the progress in abuse-deterrent technologies, it is essential to recognize that these formulations cannot eliminate the risk of opioid misuse entirely. They serve as one component of a multifaceted approach to address opioid-related challenges.

Key Market Trends

Increasing Focus on Personalized Medicine

The Global Morphine Drugs Market is witnessing a notable trend towards the increasing focus on personalized medicine, a paradigm that tailors medical treatment to individual patient characteristics. This trend is particularly relevant in the context of prescribing morphine, a powerful opioid analgesic, where individual variations in drug metabolism and response can significantly impact treatment outcomes. Personalized medicine in the context of morphine involves a comprehensive understanding of genetic factors influencing drug metabolism. Genetic variations in enzymes responsible for metabolizing morphine, such as cytochrome P450 enzymes, can lead to differences in how individuals process the drug. As a result, some patients may be more sensitive to morphine, experiencing enhanced pain relief, while others may metabolize it more rapidly, requiring adjustments in dosage to achieve the desired effect. Advancements in pharmacogenomics, the study of how genetic variations impact drug response, play a crucial role in tailoring morphine prescriptions. Genetic testing can help identify patients who may be at risk of adverse effects or those who may require higher or lower doses based on their genetic profile. This individualized approach aims to optimize pain management while minimizing the risk of side effects and improving overall patient safety and satisfaction. The integration of personalized medicine into the Global Morphine Drugs Market aligns with broader efforts in healthcare to move away from a one-size-fits-all approach and towards precision medicine. Healthcare providers are increasingly incorporating genetic information into treatment decisions, allowing for more informed and customized prescribing practices. As personalized medicine continues to gain traction, stakeholders in the Global Morphine Drugs Market are likely to witness increased collaboration between healthcare professionals, geneticists, and pharmaceutical companies. This collaborative effort aims to enhance the therapeutic benefits of morphine while addressing the inherent variability in individual patient responses, ultimately contributing to more effective and personalized pain management strategies.

Advancements in Drug Delivery Systems

Advancements in drug delivery systems are playing a pivotal role in shaping the landscape of the Global Morphine Drugs Market. These innovations are focused on enhancing the effectiveness, safety, and convenience of administering morphine, a potent opioid analgesic widely used for pain management. The evolution of drug delivery systems is driven by the imperative to optimize therapeutic outcomes while mitigating potential side effects associated with morphine use. One notable trend is the development of sustained-release formulations that offer prolonged and controlled release of morphine over an extended period. These formulations aim to provide consistent pain relief, reducing the need for frequent dosing and minimizing fluctuations in drug concentration. This not only enhances patient convenience but also contributes to improved adherence to prescribed regimens. Transdermal patches represent another significant advancement in drug delivery for morphine. These patches deliver the drug through the skin, providing a non-invasive and continuous release of morphine over an extended duration. This approach offers a valuable alternative for patients who may have difficulty with oral administration or who require a more controlled and long-lasting pain management solution. Implantable drug delivery systems are also emerging as a cutting-edge solution. These devices can be implanted subcutaneously to deliver controlled doses of morphine directly to the target site. Implantable systems offer the advantage of precise drug delivery, reducing the risk of systemic side effects and enhancing the overall efficacy of morphine therapy. Nanotechnology is increasingly being explored in the development of drug delivery systems for morphine. Nanocarriers can improve the bioavailability of morphine, enhance its solubility, and provide targeted delivery to specific tissues. This approach holds promise in optimizing the pharmacokinetics of morphine and reducing the required dosage, potentially minimizing side effects. As the Global Morphine Drugs Market continues to evolve, these advancements in drug delivery systems underscore the commitment to refining the therapeutic profile of morphine. Collaborative efforts between pharmaceutical companies, research institutions, and healthcare professionals are essential to furthering these innovations, ensuring that patients receive effective pain management with enhanced safety and convenience.

Segmental Insights

Application Insights

Based on Application, pain relief segment dominated the Global Morphine Drugs Market in 2023. This is ascribed due to to the widespread prevalence of chronic pain conditions, increasing surgical procedures, and rising awareness about effective pain management. Morphine, a potent analgesic, is a cornerstone in treating moderate to severe pain, making it a key choice for healthcare professionals. The growing aging population and rising instances of cancer contribute to the high demand for pain relief medications, solidifying the dominance of the pain relief segment in the global morphine drugs market.

Product Insights

Based on product, immediate release/short acting opioids segment dominated the Global Morphine Drugs Market in 2023. This is ascribed due to its quick onset of action, providing rapid pain relief. This characteristic makes it a preferred choice for managing acute and breakthrough pain, enhancing patient comfort. Physicians often prescribe short-acting opioids for postoperative pain, trauma, or cancer-related episodes. The flexibility in dosing and the ability to tailor treatment to individual patient needs contribute to the widespread adoption of immediate-release opioids, solidifying their dominance in the global morphine drugs market for addressing time-sensitive pain management requirements.

Regional Insights

North America dominated in the global Morphine Drugs market is attributed to several key factors. The region boasts advanced healthcare infrastructure and a well-established pharmaceutical industry. A high prevalence of pain-related conditions and a growing aging population contribute to the increased demand for morphine-based medications. Stringent regulatory standards ensure the safety and efficacy of morphine drugs, fostering trust in the market. The presence of major pharmaceutical players, substantial research and development investments, and a higher healthcare expenditure collectively propel North America to the forefront. These factors, combined with a widespread awareness of pain management, position the region as a leader in the global Morphine Drugs market..

Key Market Players

• Hikma Pharmaceuticals plc
• Pfizer Inc.
• AbbVie Inc.
• Sanofi S.A
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Endo, Inc.
• Verve Health Care Ltd.
• Mallinckrodt Pharmaceuticals

Report Scope:

In this report, the Global Morphine Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Morphine Drugs Market, By Product:

• Immediate Release/ Short Acting Opioids
• Extended Release/Long-Acting Opioids

Morphine Drugs Market, By Application:

• Pain Relief
• Anesthesia
• Cough Suppression
• Diarrhoea Suppression
• De-addiction

Morphine Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Bioprocessing Probes and Sensors Market.

Available Customizations:

Global Morphine Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Morphine Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Immediate Release/ Short Acting Opioids, Extended Release/Long-Acting Opioids)
  • 5.2.2. By Application (Pain Relief, Anaesthesia, Cough Suppression, Diarrhoea Suppression, De-addiction)
  • 5.2.3. By Company (2023)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Morphine Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Morphine Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Morphine Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Morphine Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Morphine Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Morphine Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Morphine Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Morphine Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Morphine Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Morphine Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia-Pacific Morphine Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Morphine Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Morphine Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Morphine Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Morphine Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Morphine Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. South America Morphine Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Morphine Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Morphine Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Morphine Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. Middle East and Africa Morphine Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Morphine Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Morphine Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Morphine Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
  • 10.3.4. Egypt Morphine Drugs Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Hikma Pharmaceuticals plc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. AbbVie Inc.
• 14.4. Sanofi S.A
• 14.5. Viatris Inc.
• 14.6. Sun Pharmaceutical Industries Ltd.
• 14.7. Teva Pharmaceutical Industries Ltd.
• 14.8. Endo, Inc.
• 14.9. Verve Health Care Ltd.
• 14.10. Mallinckrodt Pharmaceuticals

15. Strategic Recommendations

16. About Us & Disclaimer